Mikhail Blagosklonny studies cancer and aging. Studies within cancer and aging are some of the most complex studies. Blagosklonny earned his M.D. in internal medicine. He also received a PhD in experimental medicine and cardiology.
He received a highly honorable position as associate professor of medicine at New York Medical College. This is a platform for him to share his knowledge. He later left the platform to be senior scientist at Ordway Research Institute. When we look at some of Mikhail Blagosklonny’s methods up close we find he researches targeted cancer therapies which extend people’s lives as they only cause damage to the cancer infected cells.
He also studies biogerontology and anti-aging drugs and discovers their underlying mechanisms. According to Impact Journals, Mikhail Blagosklonny made a hypothesis about TOR signaling and linked it to playing a role in aging and cancer. The drug rapamycin is recommended to treat what is found in that particular hypothesis. It is a hypothesized treatment for life extension.
Mikhail Blagosklonny doesn’t limit himself to studying cancer but also is an editor in chief of “Aging” an open access medical journal. “Cell Cycle” is a scientific journal he also applies his editor in chief duties to and also “Oncotarget” another medical journal that covers oncology.
Blagosklonny doesn’t stop there as his work ethic shows in his credentials of publishing over 270 papers in journals his peers see.
By now it should be easy for you to see the type of man Mikhail Blagosklonny is. A over achieving and kindhearted person, A person who dedicated his life to studying just to give back. Mikhail Blagosklonny is an example for everyone.